Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Pharmaceuticals Major
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | 0.16% | 162.16 | 0.7% | $1270.30m | |
| LLY | Eli Lilly & Co. | 0.50% | 334.46 | 1.1% | $1111.09m | |
| ABBV | AbbVie, Inc. | 0.01% | 140.30 | 1.9% | $860.61m | |
| PFE | Pfizer Inc. | 0.16% | 43.18 | 0.9% | $804.94m | |
| BMY | Bristol-Myers Squibb Co. | -0.04% | 70.21 | 1.0% | $751.47m | |
| MRK | Merck & Co., Inc. | -0.37% | 87.11 | 0.7% | $695.02m | |
| AZN | AstraZeneca Plc | 1.95% | 55.98 | 1.0% | $393.72m | |
| ALNY | Alnylam Pharmaceuticals, Inc. | 0.00% | 202.37 | 8.2% | $224.83m | |
| GSK | GSK Plc | 1.70% | 30.51 | 0.3% | $212.06m | |
| NVS | Novartis AG | 0.54% | 76.45 | 0.2% | $201.99m | |
| HZNP | Horizon Therapeutics Plc | 0.00% | 67.89 | 5.4% | $188.70m | |
| IDXX | IDEXX Laboratories, Inc. | 0.00% | 346.02 | 3.9% | $184.33m | |
| GBT | Global Blood Therapeutics, Inc. | 0.00% | 68.49 | 5.4% | $178.81m | |
| SRPT | Sarepta Therapeutics, Inc. | 0.00% | 114.82 | 12.4% | $141.73m | |
| AKRO | Akero Therapeutics, Inc. | 0.00% | 39.26 | 0.0% | $134.17m |
Company Profile
Cellectis SA operates as a clinical stage biotechnological company. The firm operates through the segments: Therapeutics and Plants. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and monogenic diseases. The Plants segment focuses on using Calyxt's proprietary PlantSpringTM technology platform to engineer plant metabolism to produce innovative, high-value, and sustainable materials and products for use in helping customers meet their sustainability targets and financial goals. The company was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.